This program is supported by educational grants from Merck Sharp & Dohme Corp; Regeneron Pharmaceuticals, Inc. and Sanofi; and Taiho Oncology, Inc.
Oncology NPs, PAs, and RNs
Nikhil I. Khushalani, MD: consultant/advisor: Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar, Novartis, Pfizer, Regeneron; research support (paid to institution): Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Huya Bioscience International, Merck, Novartis, Regeneron, Replimune; individual publicly traded stocks and stock options: Amarin, Asensus Surgical, Bellicum Pharmaceuticals; other: Bristol-Myers Squibb, Celgene, Nektar, Regeneron, Replimune.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.
This program has been made available online.